Spiral Therapeutics, a clinical-stage company focused on inner ear disorders, has successfully closed a $27 million Series B financing round. The funding was led by Gund Investment and includes a strategic investment from cochlear implant leader Advanced Bionics. This capital injection, coupled with a new research collaboration, will accelerate the development of novel treatments for hearing and balance conditions.
Strategic Investment Bolsters Development
The financing round saw significant participation from both new and existing backers, signaling strong confidence in Spiral's mission. Gund Investment led the round, with Advanced Bionics and another major global pharmaceutical company joining as new strategic partners. Continued support was provided by existing investors, including Ferring Ventures and Uni-Bio Science Group, reinforcing the company's solid foundation.
Hugo Peris, Founder and CEO of Spiral Therapeutics, hailed the financing as a major milestone for the company. He noted that inner ear disorders are finally receiving the strategic attention they deserve due to their prevalence and impact. Peris emphasized that Spiral is one of a few companies with a differentiated platform capable of building a robust therapeutic pipeline.
Collaboration to Enhance Cochlear Implant Outcomes
Concurrent with the financing, Spiral Therapeutics has entered into a strategic research and development collaboration with Advanced Bionics. The partnership aims to explore sustained, local drug delivery at the time of cochlear implantation to improve patient outcomes. This initiative combines Spiral's therapeutic expertise with Advanced Bionics' global leadership in cochlear implant technology for a synergistic effect.
This joint effort seeks to create a new paradigm in treatment for individuals receiving cochlear implants. By delivering therapeutics directly to the inner ear, the collaboration could potentially enhance the function and longevity of the devices. The ultimate goal is to meaningfully improve the quality of life for a significant patient population worldwide.
Fueling a Promising Clinical Pipeline
The proceeds from the $27 million financing will be instrumental in advancing Spiral's portfolio of clinical programs. A primary focus will be the development of its lead candidate, SPT-2101, which targets Ménière's disease. The funding will also support the expansion and refinement of the company's proprietary MICS™ drug delivery platform.
SPT-2101 has already demonstrated promising results, achieving a statistically significant reduction in vertigo symptoms among patients in earlier trials. With this new capital, Spiral Therapeutics is now preparing to initiate a registrational clinical trial for the candidate. This pivotal study is a critical step on the path toward regulatory approval and market availability.
Addressing a Critical Area of Unmet Need
The field of inner ear therapeutics has historically seen limited innovation despite the high prevalence of related disorders. Spiral Therapeutics is positioned to address this significant disparity through its targeted approach to treatment. The company's focus on precision delivery technologies aims to unlock new therapeutic possibilities for a range of otologic indications.
At the core of Spiral's strategy is its Minimally-Invasive Cochlear System, or MICS™ platform. This technology is engineered to provide precise, durable, and minimally invasive exposure of therapeutics directly to the cochlea. It underpins a broad portfolio of programs designed to treat the fundamental pathobiology of hearing loss and balance disorders.
This successful Series B financing and strategic collaboration mark a pivotal moment for Spiral Therapeutics and the broader field of otology. The infusion of capital and expertise positions the company to accelerate its clinical programs and solidify its leadership in the space. With a clear focus on its innovative platform, Spiral is well-equipped to deliver transformative therapies for patients with inner ear disorders.